{"product_id":"recent-advances-in-chordoma-von-asem-shalaby","title":"Recent Advances in Chordoma","description":"\u003cp\u003eChordoma is a rare malignant bone tumour, showing  notochordal differentiation and occurs in the axial  skeleton. Brachyury, a molecule involved in  notochordal development, is a highly specific and  sensitive marker for chordoma. It is hypothesised  that brachyury or genes involved in its activation  are implicated in the pathogenesis of chordoma. As  there is no effective drug therapy for chordoma, the  aim was to identify genetic events involved in  chordoma pathogenesis with a view to identifying  potential therapeutic targets.   PI3K\/AKT\/TSC\/mTOR pathway was found activated in 65%  of chordomas, thereby providing a rationale for  testing mTOR inhibitors for the treatment of selected  cases. The fibroblastic growth factor receptor  pathway was activated in more than 90% of the  analysed cases.   Nearly half of the cases showed chromosomal  abnormalities involving the brachyury locus.  Knockdown of brachyury gene was achieved, for the  first time, in the U-CH1 chordoma cell line using  shRNA and resulted in premature cell senescence.   EGFR copy number gain was detected by FISH in 45% of  chordomas. The EGFR inhibitor, tyrphostin (AG1478)  significantly inhibited growth of the chordoma cell  line.\u003c\/p\u003e\u003cdiv class=\"aw-variant-hidden-subtitle-div\" id=\"aw-variant-subtitle-9783844394771\"\u003e\u003ch3\u003eMolecular Analysis and Identification of Therapeutic Targets\u003c\/h3\u003e\u003c\/div\u003e","brand":"Autorenwelt Shop","offers":[{"title":"Softcover - 9783844394771","offer_id":39494475513949,"sku":"9783844394771","price":59.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0940\/0622\/files\/491d66be-4e3b-4419-aa06-f47c8c7362bf.jpg?v=1770449638","url":"https:\/\/shop.autorenwelt.de\/en\/products\/recent-advances-in-chordoma-von-asem-shalaby","provider":"Autorenwelt Shop","version":"1.0","type":"link"}